Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Sulfur – selenium or tellurium compound
Reexamination Certificate
2011-08-02
2011-08-02
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Sulfur, selenium or tellurium compound
C514S740000
Reexamination Certificate
active
07989502
ABSTRACT:
Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.
REFERENCES:
patent: 2003/0171439 (2003-09-01), Lawyer et al.
patent: 2010/0074959 (2010-03-01), Hansom et al.
Reger et al. “Intranasal insulin improves cognition and modulates B-amyloid in early AD” Neurology 2008; 70: 440-448.
DeRose Jacqueline
Frey, II William Howard
Greco Mary Ann Katherine
Hanson Leah Ranae Bresin
Matthews Rachel Beth
Claytor Renee
HealthPartners Research Foundation
Osman Richard Aron
Padmanabhan Sreeni
SRI - International
LandOfFree
Intranasal delivery of modafinil does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intranasal delivery of modafinil, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intranasal delivery of modafinil will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2767033